Cargando…
Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine
Pancreatic cancer is characterized by inter-tumoral and intra-tumoral heterogeneity, especially in genetic alteration and microenvironment. Conventional therapeutic strategies for pancreatic cancer usually suffer resistance, highlighting the necessity for personalized precise treatment. Cancer vacci...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556149/ https://www.ncbi.nlm.nih.gov/pubmed/36224645 http://dx.doi.org/10.1186/s40779-022-00416-w |
_version_ | 1784807008683163648 |
---|---|
author | Huang, Xing Zhang, Gang Tang, Tian-Yu Gao, Xiang Liang, Ting-Bo |
author_facet | Huang, Xing Zhang, Gang Tang, Tian-Yu Gao, Xiang Liang, Ting-Bo |
author_sort | Huang, Xing |
collection | PubMed |
description | Pancreatic cancer is characterized by inter-tumoral and intra-tumoral heterogeneity, especially in genetic alteration and microenvironment. Conventional therapeutic strategies for pancreatic cancer usually suffer resistance, highlighting the necessity for personalized precise treatment. Cancer vaccines have become promising alternatives for pancreatic cancer treatment because of their multifaceted advantages including multiple targeting, minimal nonspecific effects, broad therapeutic window, low toxicity, and induction of persistent immunological memory. Multiple conventional vaccines based on the cells, microorganisms, exosomes, proteins, peptides, or DNA against pancreatic cancer have been developed; however, their overall efficacy remains unsatisfactory. Compared with these vaccine modalities, messager RNA (mRNA)-based vaccines offer technical and conceptional advances in personalized precise treatment, and thus represent a potentially cutting-edge option in novel therapeutic approaches for pancreatic cancer. This review summarizes the current progress on pancreatic cancer vaccines, highlights the superiority of mRNA vaccines over other conventional vaccines, and proposes the viable tactic for designing and applying personalized mRNA vaccines for the precise treatment of pancreatic cancer. |
format | Online Article Text |
id | pubmed-9556149 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-95561492022-10-13 Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine Huang, Xing Zhang, Gang Tang, Tian-Yu Gao, Xiang Liang, Ting-Bo Mil Med Res Review Pancreatic cancer is characterized by inter-tumoral and intra-tumoral heterogeneity, especially in genetic alteration and microenvironment. Conventional therapeutic strategies for pancreatic cancer usually suffer resistance, highlighting the necessity for personalized precise treatment. Cancer vaccines have become promising alternatives for pancreatic cancer treatment because of their multifaceted advantages including multiple targeting, minimal nonspecific effects, broad therapeutic window, low toxicity, and induction of persistent immunological memory. Multiple conventional vaccines based on the cells, microorganisms, exosomes, proteins, peptides, or DNA against pancreatic cancer have been developed; however, their overall efficacy remains unsatisfactory. Compared with these vaccine modalities, messager RNA (mRNA)-based vaccines offer technical and conceptional advances in personalized precise treatment, and thus represent a potentially cutting-edge option in novel therapeutic approaches for pancreatic cancer. This review summarizes the current progress on pancreatic cancer vaccines, highlights the superiority of mRNA vaccines over other conventional vaccines, and proposes the viable tactic for designing and applying personalized mRNA vaccines for the precise treatment of pancreatic cancer. BioMed Central 2022-10-13 /pmc/articles/PMC9556149/ /pubmed/36224645 http://dx.doi.org/10.1186/s40779-022-00416-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Huang, Xing Zhang, Gang Tang, Tian-Yu Gao, Xiang Liang, Ting-Bo Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine |
title | Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine |
title_full | Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine |
title_fullStr | Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine |
title_full_unstemmed | Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine |
title_short | Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine |
title_sort | personalized pancreatic cancer therapy: from the perspective of mrna vaccine |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556149/ https://www.ncbi.nlm.nih.gov/pubmed/36224645 http://dx.doi.org/10.1186/s40779-022-00416-w |
work_keys_str_mv | AT huangxing personalizedpancreaticcancertherapyfromtheperspectiveofmrnavaccine AT zhanggang personalizedpancreaticcancertherapyfromtheperspectiveofmrnavaccine AT tangtianyu personalizedpancreaticcancertherapyfromtheperspectiveofmrnavaccine AT gaoxiang personalizedpancreaticcancertherapyfromtheperspectiveofmrnavaccine AT liangtingbo personalizedpancreaticcancertherapyfromtheperspectiveofmrnavaccine |